Syon Capital LLC Grows Position in GSK plc (NYSE:GSK)

Syon Capital LLC boosted its stake in GSK plc (NYSE:GSK) by 25.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,687 shares of the pharmaceutical company’s stock after buying an additional 7,116 shares during the period. Syon Capital LLC’s holdings in GSK were worth $1,285,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 676 shares during the period. BKM Wealth Management LLC bought a new position in GSK in the fourth quarter worth approximately $32,000. Larson Financial Group LLC increased its position in GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 647 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after acquiring an additional 509 shares during the last quarter. Finally, Washington Trust Advisors Inc. purchased a new stake in shares of GSK in the 3rd quarter worth approximately $53,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.1 %

Shares of GSK traded up $0.05 during mid-day trading on Thursday, reaching $40.91. 3,015,243 shares of the company’s stock traded hands, compared to its average volume of 3,444,739. The stock’s 50-day moving average is $41.86 and its two-hundred day moving average is $38.91. The stock has a market cap of $84.78 billion, a P/E ratio of 13.58, a P/E/G ratio of 1.45 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. Research analysts forecast that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were issued a dividend of $0.3564 per share. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is presently 52.82%.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.